Document Detail


Diclofenac sodium 3% gel as a potential treatment for disseminated superficial actinic porokeratosis.
MedLine Citation:
PMID:  18702625     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Disseminated superficial actinic porokeratosis (DSAP) is a chronic cutaneous disorder of keratinization for which there is no known cure. Current therapies are often ineffective, painful, or unappealing. OBJECTIVE: To investigate the efficacy and safety of diclofenac sodium 3% gel for the treatment of DSAP. METHODS: Seventeen adult patients with a diagnosis of DSAP applied diclofenac sodium 3% gel to a target area (forearm) twice daily for 3 months up to a maximum of 6 months in an open-label, multicentre pilot study. Target area lesion counts were performed monthly, and global lesion counts were performed at baseline and at weeks 12 and 24. A treatment satisfaction questionnaire was completed at weeks 12 and 24. RESULTS: Thirteen patients completed 12 weeks of treatment and 10 completed 24 weeks. Among patients who completed 12 weeks, there was a mean decrease of 4% in target area lesions, while a mean increase of 12% was noted in global lesions. Among patients who completed 24 weeks, there was a mean increase of 19% in global lesions, but only a 10% increase noted in the target area. Seven of 13 patients had a decrease in target area lesions at week 12 and 3 of 10 patients at week 24. Questionnaire responses indicated 6 out of 10 patients would use the medication again. CONCLUSION: Target area DSAP lesions in the majority of patients treated with diclofenac sodium 3% gel (both 12 and 24 weeks) progressed to a lesser extent as compared to the global lesion count.
Authors:
S Marks; R Varma; W Cantrell; S C Chen; M Gold; M Muellenhoff; B Elewski
Related Documents :
22099035 - An endorectal balloon reduces intrafraction prostate motion during radiotherapy.
23154205 - Adolescent varicocele: is the "20/38" harbinger a durable predictor of testicular asymm...
23383695 - Head-to-head comparison between actigraph 7164 and gt1m accelerometers in adolescents.
3881125 - Efficacy in anterior uveitis of two known steroids and topical tolmetin.
3755005 - Bone disease induced by anticonvulsant therapy and treatment with calcitriol (1,25-dihy...
17280925 - A double-blind comparison of a supplemental interligamentary injection of fentanyl and ...
Publication Detail:
Type:  Journal Article; Multicenter Study    
Journal Detail:
Title:  Journal of the European Academy of Dermatology and Venereology : JEADV     Volume:  23     ISSN:  1468-3083     ISO Abbreviation:  J Eur Acad Dermatol Venereol     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2009-01-06     Completed Date:  2009-04-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9216037     Medline TA:  J Eur Acad Dermatol Venereol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  42-5     Citation Subset:  IM    
Affiliation:
Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Diclofenac / administration & dosage,  therapeutic use*
Gels
Humans
Keratosis, Actinic / drug therapy*
Pilot Projects
Porokeratosis / drug therapy*
Questionnaires
Chemical
Reg. No./Substance:
0/Gels; 15307-86-5/Diclofenac

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prisoners and skin diseases in Toulouse, France: epidemiological analysis and evaluation of life imp...
Next Document:  Proliferation, DNA repair and apoptosis in androgenetic alopecia.